2. UroToday Home
  3. Categories

Bladder Cancer

Use of Bladder Epicheck® in the follow-up of high-risk non-muscle-invasive bladder cancer: A systematic literature review.

In recent years, different urinary markers such as the Bladder Epicheck® have been developed in an attempt to reduce the number of cystoscopies in the follow-up of non-muscle invasive bladder cancer (NMIBC).

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.

The KEYNOTE-057 trial evaluated activity and safety of pembrolizumab in patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who were ineligible for or declined radical cystectomy.

A Phase 2 Pilot Study of Water Irrigation After Transurethral Resection of Bladder Tumor (WATIP) Demonstrating Safety, Feasibility and Activity - Beyond the Abstract

The underutilisation of immediate post-operative instillation of intravesical chemotherapy to reduce recurrences of non-muscle invasive bladder cancer after transurethral resection (TURBT) remains a significant and widespread problem.1-3 The latest guidelines from the European Association of Urology have incorporated a recommendation for continuous bladder irrigation to be utilised when intravesical chemotherapy is not feasible.

Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes - Beyond the Abstract

Environmental exposures are increasingly being recognized as playing a significant role in the cause of cancers. Agent Orange is a defoliant that was used to clear the jungle in the Korean and Vietnam wars and was later noted to contain a contaminant (dioxin) that is now a known carcinogen.

Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.

This study evaluated the cost-effectiveness of avelumab first-line (1L) maintenance therapy plus best supportive care (BSC) versus BSC alone for adults with locally advanced or metastatic urothelial carcinoma (la/mUC) that had not progressed following platinum-based chemotherapy in France.

Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer.

Cystoscopy is the gold standard for surveillance of non-muscle invasive bladder cancer (NMIBC), but the procedure is invasive and has suboptimal accuracy. The aim of this study was to investigate the potential of analyzing urine samples for the presence of urine tumor DNA (utDNA) to replace cystoscopy for surveillance of bladder cancer recurrence.

Does intravesical BCG for bladder cancer protect from COVID-19?

The study aimed to correlate the history of intravesical BCG as well as infantile BCG immunization with the incidence and severity of COVID-19 infection.

Retrospective data collection of patients with high-risk non muscle invasive bladder cancer (NMIBC) from two Canadian centers.

Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.

To explore pre-treatment risk factors for overall survival (OS) in advanced urothelial carcinoma (UC) patients treated with first-line (1L) chemotherapy in sequential therapy (ST) era. Additionally, to evaluate the proportion of patients who were not able to undergo subsequent immune checkpoint inhibitor (ICI) therapy according to the subgroups stratified by the risk factors.

Practice patterns and survival outcomes for Muscle-Invasive Bladder Cancer: real-life experience in a general population setting.

Bladder cancer (BC) is a common malignancy in Europe and in North America. Among BC, muscle-invasive bladder cancers (MIBC) are distinguished, as they require aggressive treatment due to their spreading potential and the poor prognosis.

J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.

The JAVELIN Bladder 100 phase 3 trial showed that avelumab first-line maintenance + best supportive care significantly prolonged overall survival and progression-free survival versus best supportive care alone in patients with advanced urothelial carcinoma who were progression-free following first-line platinum-based chemotherapy.

Page 1 of 1041